XWELL Inc

XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Treat, and Corporate and Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Treat segment consists of access to integrated care which can seamlessly fit into a post-pandemic world and is designed to deliver on-demand access to integrated healthcare through technology and personalized services, positioned for a traveler to access health care, records and real-time information all in one place. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

XWELL Inc reports revenue growth and cost efficiency in Q3

XWELL Inc delivered a solid performance in Q3 2024, marked by revenue growth, cost reduction, and strong liquidity, positioning the company for future growth.
While facing challenges such as operating losses and execution risks, XWELL's strategic initiatives and financial stability provide a foundation for overcoming obstacles.
By leveraging opportunities in brand expansion, new locations, and customer experience enhancement, XWELL can drive sustainable growth and competitive advantage in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Naples Wax Center, Treat, and Corporate & Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Naples Wax Center segment is focused on the products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.

XWELL, Inc. (NASDAQ:XWEL ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Suzanne Scrabis – Chief Financial Officer Ezra Ernst – Chief Executive Officer Conference Call Participants Operator Good day, and welcome to the XWELL, Inc. Third Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.

XWELL, Inc. (XWEL) Q3 2024 Earnings Call Transcript

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter and nine-month period ended September 30, 2024.

XWELL, Inc. Reports Third Quarter 2024 Results

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced that it will report third quarter 2024 financial results, on Thursday, November 14, 2024, after the market close. The announcement will be followed by a webcast and conference call at 5:00 p.m.

XWELL, Inc. to Report Third Quarter 2024 Results on Thursday, November 14, 2024

thredUP

P3 Health Partners Inc

The Dow Jones index closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

ThredUp And 2 Other Stocks Under $2 Executives Are Buying

Strategic leadership change will drive further growth and expansion among core business units Strategic leadership change will drive further growth and expansion among core business units

XWELL Appoints Ezra Ernst as New President and Chief Executive Officer

Partnership will bring growth opportunities and expands XpresSpa's brand to more travelers Partnership will bring growth opportunities and expands XpresSpa's brand to more travelers

XWELL Announces Partnership with Priority Pass

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (the “Company”) announced today that its Board of Directors has adopted a Tax Benefits Preservation Plan (the “Plan”) intended to preserve the value of certain of the Company's tax attributes related to previously recorded net operating losses (the “Tax Attributes”).

XWELL, Inc. Adopts Tax Benefits Preservation Plan

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the second quarter ended June 30, 2024.

XWELL, Inc. Reports Second Quarter 2024 Results

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today issued the following statement in response to CPC Pain & Wellness SPV, LLC's (“CPC”) decision to withdraw its threatened proxy fight and related lawsuit against XWELL, in connection with the Company's 2024 annual meeting of stockholders (the “2024 Annual Meeting”).

XWELL Comments on CPC's Withdrawal of Threatened Proxy Fight and Related Lawsuit

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced the closing of its previously announced registered direct offering priced at a premium to market for the issuance and sale of an aggregate of 652,705 shares of its common stock, par value $0.01 per share, at a purchase price of $2.18 per share.

XWELL Announces Closing of $1.4 Million Registered Direct Offering Priced At Premium to Market

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) --  Today, CPC Pain & Wellness SPV, LLC (“CPC”), a significant XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”) shareholder that beneficially owns 394,200 or 9.42% of XWELL's outstanding shares, issued the below letter to its fellow shareholders. The letter informs shareholders of CPC's recent lawsuit filing against the incumbent members of XWELL's Board of Directors for breach of their fiduciary duties and for the Board's wrongful and inequitable efforts to prevent CPC from nominating a competing slate of directors and consequently denying shareholders the opportunity to choose who they elect to XWELL's Board at the upcoming annual shareholder meeting. In its letter, CPC details how current Board members have personally benefited from XWELL while overseeing an astounding decline in XWELL shareholder value and substantial net losses. CPC also shares in the below letter its vision for restoring and maximizing shareholder value.

CPC Issues Letter to Fellow XWELL, Inc. Shareholders Revealing Intention Behind Recent Schedule 13D Filing & Lawsuit Against Entrenched Board of Directors

NEW YORK--(BUSINESS WIRE)--XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced that the notice materials submitted by CPC Pain & Wellness SPV, LLC (“CPC”), which purported to provide notice of CPC's intent to nominate four candidates for election to the Company's five-member Board of Directors (the “Board”) at the 2024 Annual Meeting of Stockholders, is invalid. CPC, a special purpose vehicle that was recently forme.

XWELL Announces Director Candidate Nomination Notice Submitted by CPC is Invalid

New location expands domestic footprint in busy Northeast corridor with labor lite tech forward service offerings New location expands domestic footprint in busy Northeast corridor with labor lite tech forward service offerings

XWELL Opens New XpresSpa Location at Philadelphia International Airport

Expanded service offering underscores XWELL's ongoing focus on delivering cost-effective wellness services that drive top-line growth Expanded service offering underscores XWELL's ongoing focus on delivering cost-effective wellness services that drive top-line growth

XWELL Continues to Innovate in Airport Wellness Space with New Massage Solutions: Introducing Ceragem V6 in select XpresSpa® Locations in US

NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) --  XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the first quarter ended March 31, 2024.

XWELL, Inc. Reports First Quarter 2024 Results

Pilot program designed to expand service offerings and drive revenue growth Pilot program designed to expand service offerings and drive revenue growth

XpresSpa Introduces IV Hydration Drip Therapy at Miami International Airport

XWELL, Inc. (XWEL) Q4 2023 Earnings Call Transcript

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the year ended December 31, 2023.

XWELL, Inc. Reports Fiscal Year 2023 Results

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced that it will report results for the year ended December 31, 2023, on Tuesday, April 16, 2024, after the market close. The announcement will be followed by a webcast and conference call at 5:00 p.m.

XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K for the year ended December 31, 2023. Additional time is needed for the Company to compile and analyze supporting documentation in order to finalize the Form 10-K and in order to permit the Company's independent registered public accounting firm to complete its audit of the consolidated financial statements included in the Form 10-K. The Company currently anticipates filing the Form 10-K as soon as practicable.

XWELL, Inc. Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K

Ginkgo Bioworks Holdings

The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens. BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced the appointment of Gaëlle Wizenberg to the Company's Board of Directors, effective January 1, 2024.   The Company also announced that Donald Stout, who joined XWELL's Board of Directors in 2012, will be retiring from his position.

XWELL Appoints Veteran Consumer & Wellness Entrepreneur Gaëlle Wizenberg to its Board of Directors

Eleventh international wellness center is the latest move by XWELL to expand its global footprint Eleventh international wellness center is the latest move by XWELL to expand its global footprint

XWELL Opens New XpresSpa Location in Abu Dhabi International Airport

Airport Spas Deliver Strong 39% Year-Over-Year Q3 Revenue Growth Naples Wax Center Acquisition Accelerates Future Off-Airport Growth Opportunities Further Airport Spa Expansion Internationally

XWELL, Inc. Reports Third Quarter 2023 Results

The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major U.S. airports BOSTON , Nov. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and XWELL, Inc. (Nasdaq: XWEL) today announced they are expanding their work with the U.S. Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program (TGS) to test for more than 30 additional priority pathogens, in addition to SARS-CoV-2. TGS is a flexible, multimodal platform that consists of three complementary approaches of sample collection from arriving international travelers at U.S. airports, including voluntary nasal swabbing, aircraft wastewater, and airport wastewater sampling to enhance early detection of new SARS-CoV-2 variants and other pathogens, and fills gaps in global surveillance.

News for XWELL Inc Stock (XWEL)